Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.

Publication ,  Journal Article
Segal, BH; Herbrecht, R; Stevens, DA; Ostrosky-Zeichner, L; Sobel, J; Viscoli, C; Walsh, TJ; Maertens, J; Patterson, TF; Perfect, JR; Dupont, B ...
Published in: Clin Infect Dis
September 1, 2008

Invasive fungal diseases (IFDs) have become major causes of morbidity and mortality among highly immunocompromised patients. Authoritative consensus criteria to diagnose IFD have been useful in establishing eligibility criteria for antifungal trials. There is an important need for generation of consensus definitions of outcomes of IFD that will form a standard for evaluating treatment success and failure in clinical trials. Therefore, an expert international panel consisting of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for assessing treatment responses in clinical trials of IFDs and for defining study outcomes. Major fungal diseases that are discussed include invasive disease due to Candida species, Aspergillus species and other molds, Cryptococcus neoformans, Histoplasma capsulatum, and Coccidioides immitis. We also discuss potential pitfalls in assessing outcome, such as conflicting clinical, radiological, and/or mycological data and gaps in knowledge.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

September 1, 2008

Volume

47

Issue

5

Start / End Page

674 / 683

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Microbiology
  • Humans
  • Histoplasmosis
  • Cryptococcosis
  • Coccidioidomycosis
  • Candidiasis
  • Biomedical Research
  • Aspergillosis
  • Antifungal Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Segal, B. H., Herbrecht, R., Stevens, D. A., Ostrosky-Zeichner, L., Sobel, J., Viscoli, C., … De Pauw, B. E. (2008). Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis, 47(5), 674–683. https://doi.org/10.1086/590566
Segal, Brahm H., Raoul Herbrecht, David A. Stevens, Luis Ostrosky-Zeichner, Jack Sobel, Claudio Viscoli, Thomas J. Walsh, et al. “Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.Clin Infect Dis 47, no. 5 (September 1, 2008): 674–83. https://doi.org/10.1086/590566.
Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, Walsh TJ, Maertens J, Patterson TF, Perfect JR, Dupont B, Wingard JR, Calandra T, Kauffman CA, Graybill JR, Baden LR, Pappas PG, Bennett JE, Kontoyiannis DP, Cordonnier C, Viviani MA, Bille J, Almyroudis NG, Wheat LJ, Graninger W, Bow EJ, Holland SM, Kullberg B-J, Dismukes WE, De Pauw BE. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008 Sep 1;47(5):674–683.
Journal cover image

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

September 1, 2008

Volume

47

Issue

5

Start / End Page

674 / 683

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Microbiology
  • Humans
  • Histoplasmosis
  • Cryptococcosis
  • Coccidioidomycosis
  • Candidiasis
  • Biomedical Research
  • Aspergillosis
  • Antifungal Agents